Spirax Group
Search results
Smith+Nephew is a portfolio medical technology company focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living.
Home Health Care Professionals. Products. Find a Product. Search below to find key information and resources on the purpose, benefits and application of our products and solutions, depending on your healthcare needs.
Smith+Nephew is a portfolio medical device company focused on the repair, regeneration and replacement of soft and hard tissue. Customer Portal News Investors Careers Global English
For questions about Smith+Nephew products or treatments. Note: this form is intended for healthcare professionals only.
Find out more about careers and culture at Smith+Nephew, including inclusion, diversity and equity, wellbeing, flexibility and benefits, and our current vacancies.
この度、スミス・アンド・ネフューのウェブサイトを大幅にリニューアルいたしました。. 今回のリニューアルでは、お客様がより使いやすいようにデザインや構成を見直し、機能の追加をいたしました。. リニューアルにともない、URLが変更になりましたの ...
Feb 27, 2024 · Fourth Quarter 2023 Trading Update. Our fourth quarter revenue was $1,458 million (2022: $1,365 million), up 6.4% on an underlying basis (reported revenue growth of 6.8% after 40bps foreign exchange tailwind). There were 60 trading days in the quarter, in-line with 2022.
Email:Reception.Wroclaw@smith-nephew.com We design and manufacture technology that takes the limits off living. We support healthcare professionals to return their patients to health and mobility, helping them to perform at their fullest potential.
Nov 22, 2023 · Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that it has entered into a definitive agreement to acquire CartiHeal, developer of Agili-C, a novel sports medicine technology for cartilage regeneration in the knee.
Aug 1, 2024 · Our second quarter revenue was $1,441 million (Q2 2023: $1,379 million), up 5.6% year-on-year on an underlying basis. On a reported basis this represented growth of 4.6%, including a translational -100bps headwind from foreign exchange (primarily due to the strength of the US Dollar).
